Literature DB >> 7797897

Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine.

G J Gorse1, M J Campbell, E E Otto, D C Powers, G W Chambers, F K Newman.   

Abstract

The possible enhancement of anti-influenza A virus memory cytotoxic T cell (CTL) responses to inactivated influenza virus vaccine by coadministration of intranasal live attenuated influenza A virus vaccine was investigated. Fifty elderly nursing home residents received inactivated trivalent influenza virus vaccine intramuscularly and simultaneously were randomly assigned to receive either bivalent live attenuated influenza A virus vaccine or saline placebo intranasally in a blinded fashion. A larger proportion of volunteers who received live attenuated virus vaccine than of those who received placebo experienced a postvaccination rise in anti-influenza A virus CTL activity (15 of 23 vs. 8 of 24; P < .05). Anti-influenza A virus cytotoxicity was primarily mediated by CD8+ T cells and was influenza A virus-specific and HLA-restricted. There was a possible advantage of administering live attenuated with inactivated virus vaccine because of enhanced memory anti-influenza A virus CTL activity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797897     DOI: 10.1093/infdis/172.1.1

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  In vitro analysis of virus particle subpopulations in candidate live-attenuated influenza vaccines distinguishes effective from ineffective vaccines.

Authors:  Philip I Marcus; John M Ngunjiri; Margaret J Sekellick; Leyi Wang; Chang-Won Lee
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

2.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 3.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

4.  A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Authors:  Mariana Baz; Myeisha Paskel; Yumiko Matsuoka; James R Zengel; Xing Cheng; John J Treanor; Hong Jin; Kanta Subbarao
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 5.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

Review 6.  Is there a role for a mucosal influenza vaccine in the elderly?

Authors:  E M Corrigan; R L Clancy
Journal:  Drugs Aging       Date:  1999-09       Impact factor: 3.923

Review 7.  Role of influenza vaccine for healthy children in the US.

Authors:  Stan L Block
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 8.  Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness.

Authors:  Farzaneh Sanei; Tom Wilkinson
Journal:  Ther Adv Respir Dis       Date:  2016-05-18       Impact factor: 4.031

9.  The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus.

Authors:  Amorsolo L Suguitan; Michael P Marino; Purvi D Desai; Li-Mei Chen; Yumiko Matsuoka; Ruben O Donis; Hong Jin; David E Swayne; George Kemble; Kanta Subbarao
Journal:  Virology       Date:  2009-10-14       Impact factor: 3.616

Review 10.  Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review.

Authors:  S Sehatzadeh
Journal:  Ont Health Technol Assess Ser       Date:  2012-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.